Larimar Therapeutics Reports Second Quarter 2025 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
Larimar Therapeutics, Inc. (LRMR) Tops Q2 EPS by 7c
August 14, 2025 7:24 AM EDTLarimar Therapeutics, Inc. (NASDAQ: LRMR) reported Q2 EPS of ($0.41), $0.07 better than the analyst estimate of ($0.48).
For earnings history and earnings-related data on Larimar Therapeutics, Inc. (LRMR) click here.
... More